Updates are available Correction dated 2024-01-12

Article History

Received: 11 March 2023

Accepted: 21 November 2023

First Online: 30 November 2023

Change Date: 12 January 2024

Change Type: Correction

Change Details: A Correction to this paper has been published:

Change Details: https://doi.org/10.1186/s12859-024-05642-8

Declarations

:

: The research in this manuscript was performed in accordance with relevant guidelines and regulations, including the Declaration of Helsinki. The study was approved by the United Kingdom National Research Ethics Service (NRES) Committee South Central—Berkshire under the Gynaecological Oncology Targeted Therapy Study 01 (GO-Target-01, research ethics approval #11-SC-0014) and the Oxford Ovarian Cancer-Predict Chemotherapy Response Trial (OXO-PCR-01, research ethics approval #12-SC-0404). Informed consent was obtained from all subjects.

: Not applicable.

: A.A. is the co-founder of Singula Bio Ltd. J.N. and N.H. are employees of Singula Bio Ltd. C.Y. receives remuneration as a consultant for Singula Bio Ltd. PicoCNV is the subject of United Kingdom Patent Application No. 2214524.7. The remaining authors have no competing interests to declare.